Tao Synergies Inc (TAOX)

$8.41 -0.49 (-5.51%)
Market Cap 11.69M
Revenue (ttm) 0.00
Net Income (ttm) -12.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 173,300
Avg Vol 1,223,972
Day's Range N/A - N/A
Shares Out 1.39M
Stochastic %K 14%
Beta 1.90
Analysts Strong Buy
Price Target N/A
drdudelittle
drdudelittle Jul. 25 at 8:27 PM
$TAOX Wall Street isn’t just buying Bitcoin and ETH anymore. The next frontier? AI tokens, meme coins, and classic “dino” assets. TAO has become the flagship for AI crypto treasuries: • TAO Synergies rebranded from biotech, now trades as $TAOX • Oblong raised $7.5M just to buy TAO • xTAO closed a $22.8M deal to go public and scale Bittensor BitGo now offers TAO staking. Family offices are circling. And it’s not just AI: • Bit Origin plans a $500M DOGE treasury • MEI Pharma launched a $100M Litecoin fund • HBAR, XLM, ADA, and ALGO are seeing treasury-fueled price action 🎥 Full breakdown: https://youtu.be/KmSVNHuqDQo This is the fastest rotation yet. And when the cycle turns, it won’t warn you. https://x.com/lil_disruptor/status/1948806443626377378
0 · Reply
Jpriley47
Jpriley47 Jul. 25 at 7:03 PM
$TAOX When will Tao earned through staking be reported? That should add nicely to the overall yield!
0 · Reply
teamHedge
teamHedge Jul. 25 at 3:34 PM
$TAOX only 50k volume
0 · Reply
SilentRider1
SilentRider1 Jul. 25 at 3:26 PM
$TAOX scam
0 · Reply
drdudelittle
drdudelittle Jul. 25 at 3:25 PM
$TAOX Borrow Fee Rates: Extremely high at 103.12% APR, adding pressure on short sellers.fintel.io Days to Cover: Not explicitly stated, but high short volume and low float suggest a high days-to-cover ratio, increasing squeeze risk if buying pressure surges. Conclusion: TAOX shows strong potential for a short squeeze due to high short interest, low float, and costly borrow rates, but no clear evidence confirms one is currently happening. Monitor for catalysts like news or volume spikes.
0 · Reply
teamHedge
teamHedge Jul. 25 at 3:15 PM
$TAOX
0 · Reply
Mullet_Head
Mullet_Head Jul. 25 at 1:48 PM
$TAOX …why
0 · Reply
Jpriley47
Jpriley47 Jul. 24 at 8:14 PM
$TAOX Such low volume.. Hoping for some news, high(er) volume and a push upwards!
1 · Reply
drdudelittle
drdudelittle Jul. 24 at 12:36 PM
$TAOX The estimated Short Squeeze Score for TAOX is 84/100, indicating a high risk of a short squeeze compared to the average (50). This translates to a 40–60% likelihood of a short squeeze in the near term, driven by high borrow fees (102.77% APR), low share availability (60,000 shares), and a high short volume ratio (68.17%). A catalyst, such as retail buying or positive news, could trigger significant upward price movement. The chart above visualizes the contributing factors.
0 · Reply
ChoicesNotTalent
ChoicesNotTalent Jul. 23 at 11:31 PM
$TAOX be careful. August meeting likely = dilution.
3 · Reply
Latest News on TAOX
TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today

Jul 1, 2025, 9:15 AM EDT - 26 days ago

TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today

Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy

Jun 26, 2025, 9:15 AM EDT - 4 weeks ago

Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

Jun 24, 2025, 9:15 AM EDT - 4 weeks ago

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

Jun 9, 2025, 9:00 AM EDT - 6 weeks ago

Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

Dec 20, 2024, 9:15 AM EST - 7 months ago

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

Synaptogenix Announces $5.0 Million Financing

Sep 11, 2024, 9:00 AM EDT - 11 months ago

Synaptogenix Announces $5.0 Million Financing

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Jul 18, 2024, 9:00 AM EDT - 1 year ago

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Jun 26, 2024, 9:00 AM EDT - 1 year ago

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

May 7, 2024, 9:00 AM EDT - 1 year ago

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Apr 24, 2024, 9:15 AM EDT - 1 year ago

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Apr 3, 2024, 8:00 AM EDT - 1 year ago

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Synaptogenix President Daniel L. Alkon, M.D.

Dec 19, 2023, 9:00 AM EST - 1 year ago

Synaptogenix President Daniel L. Alkon, M.D.

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

Dec 6, 2023, 9:00 AM EST - 1 year ago

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology

Nov 2, 2023, 9:00 AM EDT - 1 year ago

Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology

Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease

Sep 26, 2023, 9:00 AM EDT - 1 year ago

Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease

Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study

Sep 7, 2023, 9:00 AM EDT - 2 years ago

Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

Jul 19, 2023, 9:00 AM EDT - 2 years ago

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience

Jul 13, 2023, 9:00 AM EDT - 2 years ago

Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience

Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities

Mar 7, 2023, 9:00 AM EST - 2 years ago

Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities

5 Health Care Stocks That Are Diving - And May Rally

Jan 19, 2023, 8:58 AM EST - 2 years ago

5 Health Care Stocks That Are Diving - And May Rally

FATE IPSC TECH

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

Dec 16, 2022, 9:00 AM EST - 2 years ago

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

Synaptogenix: Bryostatin For Alzheimer's, As Binary As Can Be

Dec 9, 2022, 11:50 AM EST - 2 years ago

Synaptogenix: Bryostatin For Alzheimer's, As Binary As Can Be

Synaptogenix Announces $15 Million Private Placement with Existing Investors

Nov 18, 2022, 9:00 AM EST - 2 years ago

Synaptogenix Announces $15 Million Private Placement with Existing Investors

Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022

Oct 19, 2022, 9:00 AM EDT - 3 years ago

Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022

Synaptogenix Welcomes Lecanemab Phase 3 Trial Results

Sep 28, 2022, 11:50 AM EDT - 3 years ago

Synaptogenix Welcomes Lecanemab Phase 3 Trial Results

Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network

Aug 12, 2022, 9:00 AM EDT - 3 years ago

Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network

Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

Jul 26, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

Synaptogenix Announces Corporate Update Conference Call

Jul 21, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix Announces Corporate Update Conference Call

Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data

Jul 20, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data

Synaptogenix to Present at the Cell Symposium

May 17, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix to Present at the Cell Symposium

Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial

Apr 19, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial

New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease

Apr 5, 2022, 9:15 AM EDT - 3 years ago

New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease

Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit

Mar 29, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit

Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum

Mar 22, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum

Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

Mar 15, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis

Feb 23, 2022, 9:15 AM EST - 3 years ago

Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis

Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients

Feb 1, 2022, 9:15 AM EST - 3 years ago

Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients

Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment

Nov 16, 2021, 11:07 PM EST - 4 years ago

Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment

5 Short Squeeze Candidates To Watch: Huadi Tops List, Altimeter Group And Bit Digital Rejoin Leaderboard

Nov 15, 2021, 9:28 AM EST - 4 years ago

5 Short Squeeze Candidates To Watch: Huadi Tops List, Altimeter Group And Bit Digital Rejoin Leaderboard

BTBT HUDI

Rebuilding Connections, Fostering Growth: Synaptogenix Could Be A Beacon of Hope for Patients With Neurological Diseases

Oct 5, 2021, 9:14 AM EDT - 4 years ago

Rebuilding Connections, Fostering Growth: Synaptogenix Could Be A Beacon of Hope for Patients With Neurological Diseases

Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference

Sep 10, 2021, 9:00 AM EDT - 4 years ago

Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference

Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome

Aug 5, 2021, 10:00 AM EDT - 4 years ago

Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome

Synaptogenix Stock Drops After Unveiling Analyses Of Alzheimer's Candidate

Jul 26, 2021, 1:47 PM EDT - 4 years ago

Synaptogenix Stock Drops After Unveiling Analyses Of Alzheimer's Candidate

Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021

Jul 26, 2021, 9:15 AM EDT - 4 years ago

Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021

Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings

Jul 21, 2021, 9:00 AM EDT - 4 years ago

Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings

Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline

Jul 14, 2021, 9:00 AM EDT - 4 years ago

Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline

Synaptogenix Announces Regenerative Patent Award to Treat Alzheimer's Disease

Jul 7, 2021, 9:00 AM EDT - 4 years ago

Synaptogenix Announces Regenerative Patent Award to Treat Alzheimer's Disease

Synaptogenix: The Next Big Thing In Alzheimer's

Jun 16, 2021, 4:06 PM EDT - 4 years ago

Synaptogenix: The Next Big Thing In Alzheimer's

Synaptogenix Announces $12.5 Million Private Placement

Jun 14, 2021, 9:00 AM EDT - 4 years ago

Synaptogenix Announces $12.5 Million Private Placement

Synaptogenix's Alzheimer's Candidate Displays Signs Of Safety In Mid-Stage Study

Jun 9, 2021, 1:25 PM EDT - 4 years ago

Synaptogenix's Alzheimer's Candidate Displays Signs Of Safety In Mid-Stage Study

drdudelittle
drdudelittle Jul. 25 at 8:27 PM
$TAOX Wall Street isn’t just buying Bitcoin and ETH anymore. The next frontier? AI tokens, meme coins, and classic “dino” assets. TAO has become the flagship for AI crypto treasuries: • TAO Synergies rebranded from biotech, now trades as $TAOX • Oblong raised $7.5M just to buy TAO • xTAO closed a $22.8M deal to go public and scale Bittensor BitGo now offers TAO staking. Family offices are circling. And it’s not just AI: • Bit Origin plans a $500M DOGE treasury • MEI Pharma launched a $100M Litecoin fund • HBAR, XLM, ADA, and ALGO are seeing treasury-fueled price action 🎥 Full breakdown: https://youtu.be/KmSVNHuqDQo This is the fastest rotation yet. And when the cycle turns, it won’t warn you. https://x.com/lil_disruptor/status/1948806443626377378
0 · Reply
Jpriley47
Jpriley47 Jul. 25 at 7:03 PM
$TAOX When will Tao earned through staking be reported? That should add nicely to the overall yield!
0 · Reply
teamHedge
teamHedge Jul. 25 at 3:34 PM
$TAOX only 50k volume
0 · Reply
SilentRider1
SilentRider1 Jul. 25 at 3:26 PM
$TAOX scam
0 · Reply
drdudelittle
drdudelittle Jul. 25 at 3:25 PM
$TAOX Borrow Fee Rates: Extremely high at 103.12% APR, adding pressure on short sellers.fintel.io Days to Cover: Not explicitly stated, but high short volume and low float suggest a high days-to-cover ratio, increasing squeeze risk if buying pressure surges. Conclusion: TAOX shows strong potential for a short squeeze due to high short interest, low float, and costly borrow rates, but no clear evidence confirms one is currently happening. Monitor for catalysts like news or volume spikes.
0 · Reply
teamHedge
teamHedge Jul. 25 at 3:15 PM
$TAOX
0 · Reply
Mullet_Head
Mullet_Head Jul. 25 at 1:48 PM
$TAOX …why
0 · Reply
Jpriley47
Jpriley47 Jul. 24 at 8:14 PM
$TAOX Such low volume.. Hoping for some news, high(er) volume and a push upwards!
1 · Reply
drdudelittle
drdudelittle Jul. 24 at 12:36 PM
$TAOX The estimated Short Squeeze Score for TAOX is 84/100, indicating a high risk of a short squeeze compared to the average (50). This translates to a 40–60% likelihood of a short squeeze in the near term, driven by high borrow fees (102.77% APR), low share availability (60,000 shares), and a high short volume ratio (68.17%). A catalyst, such as retail buying or positive news, could trigger significant upward price movement. The chart above visualizes the contributing factors.
0 · Reply
ChoicesNotTalent
ChoicesNotTalent Jul. 23 at 11:31 PM
$TAOX be careful. August meeting likely = dilution.
3 · Reply
luigiovine
luigiovine Jul. 23 at 7:02 PM
$TAOX Databricks market value 62 billion dollars is on subnet 46. More richest company will be on Bittensor subnets in briefly time.
1 · Reply
drdudelittle
drdudelittle Jul. 23 at 4:42 PM
$TAOX $TAO hitting $600–$800, boosting TAOX NAV Retail/institutional buying vs. illiquid stock High borrow fees (99.61% APR) & low short shares (85K)Monitor short squeeze score, borrow rates on Fintel, & $TAO on exchanges. High risk, high reward! $TAOX #TAO #ShortSqueeze
0 · Reply
SilentRider1
SilentRider1 Jul. 23 at 3:51 PM
$TAOX and what for the future of TAOX synaptogenics?
2 · Reply
luigiovine
luigiovine Jul. 23 at 3:28 PM
$TAOX Quantum subnet @qBitTensor changed the game. Mining is no longer about who has more GPUs. It’s about who’s smarter. This will attract talent, not just capital. If you want proof this isn’t fluff, here’s what they just published: qbittensorlabs.com
2 · Reply
Geromino
Geromino Jul. 23 at 2:52 PM
$TAOX sell orders set high, f’m
1 · Reply
drdudelittle
drdudelittle Jul. 23 at 2:02 PM
$TAOX SHORT SQUEEZE ALERT! Borrow fees hit 99.61% (down from 107.43% yesterday) with only 85,000 shares left to borrow (from 200K). Off-exchange short volume at 74K (53.43% ratio) on 7/22. AI-crypto pivot heats up—cover risk rising? #TAO #ShortSqueeze
1 · Reply
drdudelittle
drdudelittle Jul. 22 at 6:54 PM
$TAOX $TAOX's 108.59% borrow fee signals intense short-selling pressure and possible squeeze risk (Wikipedia). At $8.82 per share, it costs $0.026/day to borrow, based on that rate. As of July 21, 55% of trades were shorted—while not a standard metric, this indicates notable bearish positioning. The float is just 1.39M shares (SoFi), limiting public availability and increasing volatility and squeeze potential. TAOX holds and stakes $TAO, which trades at $441.08; if $TAO rises, TAOX could benefit directly. FINRA short interest data—expected around July 24 (MarketBeat)—may provide key clarity. Earnings are scheduled for August 8 (TradingView), offering another potential catalyst. #ShortSqueeze
2 · Reply
Corona76ers
Corona76ers Jul. 22 at 2:33 PM
$TAOX $OBLG $TAO.X xtao company just listed on Canadian exchange https://money.tmx.com/en/quote/XTAO.U https://www.accessnewswire.com/newsroom/en/blockchain-and-cryptocurrency/xtao-announces-public-listing-on-tsx-venture-exchange-and-22.8m-usd-f-1050355
1 · Reply
TopNI
TopNI Jul. 22 at 1:38 PM
$TAOX all i can see is shaking a tree for apples
0 · Reply
SilentRider1
SilentRider1 Jul. 22 at 1:11 PM
$TAOX yes
0 · Reply
Geromino
Geromino Jul. 22 at 12:47 PM
$TAOX volatile little shit ain’t it
0 · Reply
SilentRider1
SilentRider1 Jul. 22 at 11:36 AM
$TAOX going down
0 · Reply